Summary
Isotechnika Inc. (Isotechnika) is a biopharmaceutical company which is principally focused on the discovery, development and commercialization of new immunosuppressive drugs for the treatment of autoimmune diseases and the company also operates in a diagnostic business segment. Voclosporin, the company's lead product is a next generation calcineurin inhibitor. Isotechnika is working towards building a solid and complementary drug pipeline. Isotechnika Pharma Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol ISA. Isotechnika currently has been issued 190 patents related to voclosporin and has 55 patents pending related to this compound. The company is headquartered in Alberta, Canada.
Isotechnika Pharma Inc. Key Recent Developments…
Apr 25, 2011: Isotechnika Pharma Reports Net Loss Of CAD2.4m For Q4 2010
Feb 18, 2011: Isotechnika Pharma Appoints Peter Wijngaard And HeungJoon Yang To Board
Nov 09, 2010: Isotechnika Reports Net Loss Of CAD1.55 Million For Q3 2010
Aug 11, 2010: Isotechnika Reports Net Loss Of CAD0.5 Million For Q2 2010
Jun 23, 2010: Fda Further Clarifies Lux Biosciences Advisory Committee Meeting Cancellation
This comprehensive SWOT profile of Isotechnika Pharma Inc. provides you an indepth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by Company to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description – A detailed description of the company’s operations and business divisions.
Corporate strategy – Analyst’s summarization of the company’s business strategy.
SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history – Progression of key events associated with the company.
Major products and services – A list of major products, services and brands of the company.
Key competitors – A list of key competitors to the company.
Key employees – A list of the key executives of the company.
Executive biographies – A brief summary of the executives’ employment history.
Key operational heads – A list of personnel heading key departments/functions.
Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities – A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.
For more information, please visit:
http://www.aarkstore.com/reports/Isotechnika-Pharma-Inc-ISA-Financial-and-Strategic-SWOT-Analysis-Review-13688.html
Or email us at contact@aarkstore.com or call +918149852585
Related reports
http://www.aarkstore.com/search/viewresults.asp?search=Isotechnika%20Pharma%20Inc&PubId=&pagenum=1
Aarkstore Enterprise
Tel : +912227453309
Mobile No:+08149852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://www.emarketreports.com
Follow us on twitter: http://twitter.com/aarkstoredotcom
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstoreenterprise
Isotechnika Inc. (Isotechnika) is a biopharmaceutical company which is principally focused on the discovery, development and commercialization of new immunosuppressive drugs for the treatment of autoimmune diseases and the company also operates in a diagnostic business segment. Voclosporin, the company's lead product is a next generation calcineurin inhibitor. Isotechnika is working towards building a solid and complementary drug pipeline. Isotechnika Pharma Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol ISA. Isotechnika currently has been issued 190 patents related to voclosporin and has 55 patents pending related to this compound. The company is headquartered in Alberta, Canada.
Isotechnika Pharma Inc. Key Recent Developments…
Apr 25, 2011: Isotechnika Pharma Reports Net Loss Of CAD2.4m For Q4 2010
Feb 18, 2011: Isotechnika Pharma Appoints Peter Wijngaard And HeungJoon Yang To Board
Nov 09, 2010: Isotechnika Reports Net Loss Of CAD1.55 Million For Q3 2010
Aug 11, 2010: Isotechnika Reports Net Loss Of CAD0.5 Million For Q2 2010
Jun 23, 2010: Fda Further Clarifies Lux Biosciences Advisory Committee Meeting Cancellation
This comprehensive SWOT profile of Isotechnika Pharma Inc. provides you an indepth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by Company to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description – A detailed description of the company’s operations and business divisions.
Corporate strategy – Analyst’s summarization of the company’s business strategy.
SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history – Progression of key events associated with the company.
Major products and services – A list of major products, services and brands of the company.
Key competitors – A list of key competitors to the company.
Key employees – A list of the key executives of the company.
Executive biographies – A brief summary of the executives’ employment history.
Key operational heads – A list of personnel heading key departments/functions.
Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities – A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.
For more information, please visit:
http://www.aarkstore.com/reports/Isotechnika-Pharma-Inc-ISA-Financial-and-Strategic-SWOT-Analysis-Review-13688.html
Or email us at contact@aarkstore.com or call +918149852585
Related reports
http://www.aarkstore.com/search/viewresults.asp?search=Isotechnika%20Pharma%20Inc&PubId=&pagenum=1
Aarkstore Enterprise
Tel : +912227453309
Mobile No:+08149852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://www.emarketreports.com
Follow us on twitter: http://twitter.com/aarkstoredotcom
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstoreenterprise
No comments:
Post a Comment